Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors

Journal of Thoracic Oncology

Volumn 12, Issue 11, 2017, Pages 1654-1663

  Marchetti, Antonio ^a   Barberis, Massimo ^b   Franco, Renato ^c   De Luca, Graziano ^a   Pace, Maria Vittoria ^a   Staibano, Stefania ^d   Volante, Marco ^e   Buttitta, Fiamma ^a   Guerini Rocco, Elena ^b   Righi, Luisella ^e   D'antuono, Tommaso ^a   Scagliotti, Giorgio V ^e   Pinto, Carmine ^f   De Rosa, Gaetano ^d   Papotti, Mauro ^e  

^a UNIVERSITY OF CHIETI   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

Immunohistochemistry; Immunotherapy; Non small cell lung cancer; PD 1; PD L1

Indexed keywords

CHECKPOINT KINASE INHIBITOR; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MULTICENTER STUDY; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TISSUE MICROARRAY; CLINICAL TRIAL; IMMUNOLOGY; IMMUNOTHERAPY; LUNG TUMOR; METABOLISM; PATHOLOGY; PROCEDURES;

ANTIBODIES, MONOCLONAL; B7-H1 ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LUNG NEOPLASMS;

EID: 85029164781     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2017.07.031     Document Type: Article

References (33)

1. US Food and Drug and Administration. FDA approved drug products. http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125527. Accessed March 2017.
2. US Food and Drug Administration. FDA approves Keytruda for advanced non-small cell lung cancer. https://www.fda.gov/newsevents/newsroom/pressansupnouncements/ucm465444.htm. Accessed October 2, 2015.
3. US Food and Drug Administration. Atezolizumab (TECENTRIQ). https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm525780. Accessed October 18, 2016.
4. European medicines agency. Opdivo. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/003985/WC500194111.pdf. Accessed September 24, 2015.
5. European medicines agency. Keytruda. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/003820/WC500209310.pdf. Accessed June 23, 2016.
6. US Food and Drug Administration. Pembrolizumab (KEYTRUDA) checkpoint inhibitor. https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm526430. Accessed October 24, 2016.
7. European medicines agency. Keytruda. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/003820/WC500218016.pdf. Accessed December 15, 2016.
8. Antonia, S., Goldberg, S.B., Balmanoukian, A., et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol 17 (2016), 299–308.
9. Planchard, D., Yokoi, T., McCleod, M.J., et al. A phase III study of durvalumab (MEDI4736) with or without tremelimumab for previously treated patients with advanced NSCLC: rationale and protocol design of the Arctic study. Clin Lung Cancer 17 (2016), 232–236.e231.
10. Jerusalem, G., Chen, F., Spigel, D., et al. Oa03.03 javelin solid tumor: OA03.03 JAVELIN solid tumor: safety and clinical activity of avelumab (anti-PD-L1) as first-line treatment in patients with advanced NSCLC. J Thorac Oncol, 12, 2017, S252.
11. Grigg, C., Rizvi, N.A., PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?. J Immunother Cancer, 4, 2016, 48.
12. Patel, S.P., Kurzrock, R., PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 14 (2015), 847–856.
13. Abdel-Rahman, O., Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: a meta-analysis. Crit Rev Oncol Hematol 101 (2016), 75–85.
14. Carbognin, L., Pilotto, S., Milella, M., et al. Differential activity of nivolumab, pembrolizumab and mpdl3280a according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One, 10, 2015, e0130142.
15. Sacher, A.G., Gandhi, L., Biomarkers for the clinical use of PD-1/PD-L1 inhibitors in non-small-cell lung cancer: a review. JAMA Oncol 2 (2016), 1217–1222.
16. Gridelli, C., Ascierto, P.A., Barberis, M.C., et al. Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian Association of Thoracic Oncology. Expert Opin Biol Ther 16 (2016), 1479–1489.
17. US Food and Drug Administration. Premarket approval (PMA). http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P150027. Accessed January 23, 2016.
18. Roche. Ventana. http://www.accessdata.fda.gov/cdrh_docs/pdf16/p160006c.Pdf. Accessed October 21, 2016.
19. Dako. PD-L1 IHC 22C3 pharmDx. https://www.agilent.com/cs/library/packageinsert/public/P03951%20rev%2004.pdf. Accessed October 2, 2016.
20. Neuman, T., London, M., Kania-Almog, J., et al. A harmonization study for the use of 22C3 PD-L1 immunohistochemical staining on Ventana's platform. J Thorac Oncol 11 (2016), 1863–1868.
21. Hirsch, F.R., McElhinny, A., Stanforth, D., et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol 12 (2017), 208–222.
22. Scheel, A.H., Dietel, M., Heukamp, L.C., et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol 29 (2016), 1165–1172.
23. Ratcliffe, M.J., Sharpe, A., Midha, A., et al. Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cut-offs in non-small cell lung cancer. Clin Cancer Res 23 (2017), 3585–3591.
24. Adam, J., Rouquette, I., Damotte, D., et al. Multicentric French harmonization study for PD-L1 IHC testing in NSCLC abstract PLO4a. J Thorac Oncol 12 (2016), S11–S12.
25. Shrout, P.E., Fleiss, J.L., Intraclass correlations: uses in assessing rater reliability. Psychol Bull 86 (1979), 420–428.
26. Hallgren, K.A., Computing Inter-rater reliability for observational data: an overview and tutorial. Tutor Quant Methods Psychol 8 (2012), 23–34.
27. Lin, L.I.-K., A concordance correlation coefficient to evaluate reproducibility. Biometrics 45 (1989), 255–268.
28. Fitzgibbons, P.L.1, Bradley, L.A., Fatheree, L.A., et al. College of American Pathologists Pathology and Laboratory Quality Center. Principles of analytic validation of immunohistochemical assays: guideline from the College of American Pathologists Pathology and Laboratory Quality Center. Arch Pathol Lab Med 138 (2014), 1432–1443.
29. Brahmer, J.R., Tykodi, S.S., Chow, L.Q., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366 (2012), 2455–2465.
30. Garon, E.B., Rizvi, N.A., Hui, R., et al. Pembrolizumab for the treatment of non-small cell lung cancer. N Engl J Med 372 (2015), 2018–2028.
31. Reck, M., Rodríguez-Abreu, D., Robinson, A.G., et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375 (2016), 1823–1833.
32. Herbst, R.S., Baas, P., Kim, D.W., et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 (2016), 1540–1550.
33. Wu, S., Shi, X., Sun, J., et al. The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma. Oncotarget 8 (2017), 16421–16429.